SMAD2 and cancer: Specifically, we noted a 78-fold increase above expected in “Reactome pathway SMAD2/3 Phosphorylation Motif Mutants in Cancer” (R-HSA-3304356), and the related “TGFΒR1 KD Mutants in Cancer” (R-HSA-3656532), “Loss of Function of TGFΒR1 in Cancer” (65-fold, R-HSA-3656534), “Loss of Function of SMAD2/3 in Cancer” (65-fold, R-HSA-3304349), and “TGF-β Receptor Complex in Cancer” (56-fold, R-HSA-3304351) (respectively, highlighted in magenta, green, blue, orange, and brown in Figure 6L).